Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

Clinical trial NCT06926790 · RECRUITING

Trial details

NCT number: NCT06926790
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer - Non Small Cell

Start date: 2025-02-17
Primary completion: 2030-03-31
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.